{"nctId":"NCT00475852","briefTitle":"A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure","startDateStruct":{"date":"2007-05"},"conditions":["Heart Decompensation"],"count":7141,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Nesiritide"]},{"label":"002","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Nesiritide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nHospitalized for the management of acute decompensated heart failure (ADHF) or diagnosed with ADHF within 48 hours after being hospitalized for another reason; Diagnosis of ADHF is defined as dyspnea (difficulty breathing) at rest or dyspnea with minimal activity.\n\nExclusion Criteria:\n\nAt high risk for hypotension (low blood pressure); Acute coronary syndrome as primary diagnosis; History of cardiac valvular stenosis, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or pericardial tamponade; Previous enrollment in a nesiritide study; Persistent, uncontrolled hypertension (SBP \\[systolic blood pressure\\] \\>180 mmHg).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":null},{"groupId":"OG001","value":"345","spread":null}]}]}]},{"type":"PRIMARY","title":"Dyspnea Self-Assessment at 6 Hours After Initiation of Study Drug","description":"Dyspnea symptoms were measured by patient self-assessed Likert scale at 6 hours after study drug initiation.The Likert scale is a 7-point ordinal categorical scale (the 7 categories are markedly better, moderately better, minimally better, unchanged, minimally worse, moderately worse, and markedly worse.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"513","spread":null},{"groupId":"OG001","value":"460","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1007","spread":null},{"groupId":"OG001","value":"989","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1119","spread":null},{"groupId":"OG001","value":"1174","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"692","spread":null},{"groupId":"OG001","value":"748","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"Dyspnea Self-Assessment at 24 Hours After Initiation of Study Drug","description":"Dyspnea symptoms were measured by patient self-assessed Likert scale at 24 hours after study drug initiation. The Likert scale is a 7-point ordinal categorical scale (the 7 categories are markedly better, moderately better, minimally better, unchanged, minimally worse, moderately worse, and markedly worse.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1025","spread":null},{"groupId":"OG001","value":"935","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1274","spread":null},{"groupId":"OG001","value":"1313","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"716","spread":null},{"groupId":"OG001","value":"751","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null},{"groupId":"OG001","value":"323","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Well-Being Self-Assessment at 6 Hours After Initiation of Study Drug","description":"Overall well-being was measured by patient self-assessed Likert scale at 6 hours after study drug initiation. The Likert scale is a 7-point ordinal categorical scale (the 7 categories are markedly better, moderately better, minimally better, unchanged, minimally worse, moderately worse, and markedly worse.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"449","spread":null},{"groupId":"OG001","value":"418","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"962","spread":null},{"groupId":"OG001","value":"965","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1154","spread":null},{"groupId":"OG001","value":"1186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"751","spread":null},{"groupId":"OG001","value":"785","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Well-Being Self-Assessment at 24 Hours After Initiation of Study Drug","description":"Overall well-being was measured by patient self-assessed Likert scale at 24 hours after study drug initiation. The Likert scale is a 7-point ordinal categorical scale (the 7 categories are markedly better, moderately better, minimally better, unchanged, minimally worse, moderately worse, and markedly worse.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"913","spread":null},{"groupId":"OG001","value":"843","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1297","spread":null},{"groupId":"OG001","value":"1311","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"761","spread":null},{"groupId":"OG001","value":"798","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"331","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of Persistent or Worsening Heart Failure and All-Cause Mortality","description":"Clinical manifestations of worsening or persistent decompensated heart failure were defined by at least one of the following: new, persistent or worsening: dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, pulmonary basilar rales/crackles, jugular venous distension, renal hypoperfusion with no other apparent cause, or radiologic evidence of worsening heart failure. And was also defined by a new therapy specifically for the treatment of worsening or persistent decompensated heart failure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Alive and Outside the Hospital","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":"6.88"},{"groupId":"OG001","value":"20.7","spread":"7.05"}]}]}]},{"type":"SECONDARY","title":"Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null},{"groupId":"OG001","value":"402","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"All-Cause Mortality Through Day 30","description":"All deaths were adjudicated by an independent Clinical Events Committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"All-Cause Mortality Through Day 180","description":"All deaths were adjudicated by an independent Clinical Events Committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"429","spread":null},{"groupId":"OG001","value":"447","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cardiovascular Mortality Through Day 30","description":"All deaths were adjudicated by an independent Clinical Events Committee (CEC) and the cardiovascular deaths were classified by the CEC based on the primary causes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Renal Impairment","description":"Renal impairment was defined as a greater than 25% decrease from baseline in the Modification of Diet in Renal Disease calculated glomerular filtration rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1032","spread":null},{"groupId":"OG001","value":"968","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":3498},"commonTop":["Atrial Fibrillation","Ventricular Tachycardia","Pneumonia","Myocardial Infarction","Ischaemic Stroke"]}}}